D
elirium is a syndrome characterized by disturbances of consciousness, attention, cognition, and perception that develops over a short period and tends to fluctuate throughout a day (1) . It is one of the most common central nervous system disorders in elderly patients after surgery (2) . The reported incidence ranged from 15% to 53% in elderly postoperative patients, and it was as high as 80% in those who required intensive care (3) (4) (5) . A review analysis by Dyer et al (6) showed that the average incidence of postoperative delirium was 36.8%, and the prevalence increased with age.
The occurrence of delirium is associated with worse outcomes of patients, i.e., they had poorer functional recovery, more frequent complications, longer hospital stays, higher mortality rates, and greater hospital costs (7) (8) (9) (10) (11) . Furthermore, delirium has negative impacts on patients' long-term outcomes, even though its symptoms are usually transient. It has been noticed that patients with early postoperative delirium tended to have long-term cognitive impairment and lowered quality of life (12, 13) .
Considering the facts that the population is aging and the number of elderly patients undergoing surgery is increasing (14) , finding measures to prevent postoperative delirium is of utmost importance. Various pharmacologic agents (such as antipsychotics, acetylcholinesterase inhibitors, sleep-wake cycle regulators, and others) have been assessed for potential roles in postoperative delirium prevention (15) (16) (17) (18) (19) (20) (21) . However, the results from these studies are inconsistent. In a more recent study, Larsen et al (22) found that prophylactic olanzapine (an atypical antipsychotic) reduced the incidence of postoperative delirium in elderly joint replacement patients. But, in patients who had delirium develop, delirium lasted longer and was more severe in the olanzapine group. To date no recommendation can be made for a drug's routine clinical use to prevent delirium (23, 24) .
Haloperidol is a typical antipsychotic and has been used widely to treat the established delirium (25) . In a small nonblinded study, haloperidol prophylaxis (5 mg intravenously for 5 consecutive postoperative days) was proved effective in reducing postoperative delirium in gastrointestinal surgery patients (26) . Subsequently, Kalisvaart et al (15) performed a randomized controlled trial in 430 elderly hip surgery patients. Haloperidol prophylaxis (0.5 mg orally three times daily) was started preoperatively and continued for up to 3 days after surgery. Their results showed that haloperidol decreased the severity and duration, but not the incidence, of postoperative delirium. Therefore, further study was needed to determine the efficacy of haloperidol in delirium prevention (27) .
The difference in haloperidol dosage used in these two studies perhaps can explain the inconsistent results. Because the oral bioavailability of haloperidol is only 35% to 60% (28, 29) , it is possible that the dosage of haloperidol used in the study of Kalisvaart et al (15) was too small to prevent delirium. Furthermore, studies showed that postoperative delirium mainly occurred in the early postoperative period. The number of new delirium cases was highest on the first postoperative day and then decreased rapidly over time (8, 30) . We therefore hypothesized that short-term use of lowdose intravenous haloperidol might be effective in preventing postoperative delirium. The purpose of this study was to determine the efficacy and safety of shortterm administration of low-dose intravenous haloperidol in preventing delirium in critically ill elderly patients after noncardiac surgery.
MATERIALS AND METHODS

Study Design
This was a prospective, randomized, double-blind, and placebo-controlled two-center clinical trial. The study protocol was approved by the local Clinical Research Ethics Committees. Written informed consent was obtained from each patient or, if the patient could not provide informed consent, from the surrogate of the patient. The study was conducted from June 2009 to May 2010 in intensive care units (ICUs) of two large tertiary teaching hospitals in Beijing, China.
Patient Recruitment and Randomization
Patients 65 yrs or older who were admitted to the ICU after noncardiac surgery were screened consecutively. The exclusion criteria included: preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, or levodopa treatment; inability to communicate in the preoperative period (coma, profound dementia, or language barrier); use of haloperidol or other neuroleptics during or after anesthesia; neurosurgery; individuals unlikely to survive for Ͼ24 hrs; and prolonged corrected QT (QTc) interval of 460 ms or higher for men and 470 ms or higher for women on the baseline electrocardiogram.
Randomization was stratified by center. Eligible patients were sequentially randomly assigned to either haloperidol group or placebo group according to computer-generated randomization codes. Detailed information including baseline demographics, preoperative medical history, admission diagnosis, severity of illness, as well as perioperative variables were obtained at the time of enrollment.
Study Drug Administration and Procedures
Study drug was prepared by an independent nurse with either haloperidol (5 mg diluted with normal saline to a final concentration of 0.1 mg/mL) or placebo (normal saline), and was prepackaged according to the randomization code. Placebo medication was identical in the appearance to the active drug. Trial medication was started within 1 hr after enrollment and continued for 12 hrs. Study drug was administrated intravenously by bolus injection of 5 mL (0.5 mg haloperidol or placebo), followed by continuous infusion at a rate of 1 mL/hr (0.1 mg/hr haloperidol or placebo).
All study personnel, healthcare team members, and patients were unaware of treatment group assignment, and blinding was maintained throughout the whole study period. Code envelopes were stored at the site of investigation. In case of emergency, attending intensivist for patient care could request unmasking of the treatment allocation. A statement had to be made in the case report formulary in that case. Study drug was discontinued if life-threatening drug-related adverse events (such as torsades de pointes, or other ventricular tachycardia requiring treatment) occurred. These patients would be included in the final intention-to-treat analyses.
Postoperative analgesia routinely included patient-controlled epidural analgesia (established with 250 mL of 0.12% ropivacaine plus 0.5 g/mL sufentanil, programmed to deliver a 2-mL bolus with a lockout interval of 20 mins and a background infusion of 4 mL/hr) or patient-controlled intravenous analgesia (established with 100 mL of 0.5 mg/mL morphine, programmed to deliver a 2-mL bolus with a lockout interval of 6 -10 mins and a background infusion of 1 mL/hr). Supplemental analgesia was administered with fentanyl if necessary (25 g every 10 mins to a 1-hr maximum of 150 g, with or without continuous infusion started at 12.5 g/hr). For patients with endotracheal tubes, intravenous sedatives including propofol or midazolam were administrated continuously and titrated by bedside nurses to a target sedation level (Richmond Agitation Sedation Scale range, Ϫ2 to ϩ 1) (31, 32) . Daily awakening was used for those who were not extubated in the morning. No other analgesics or sedatives were allowed during the study period.
For all patients, multicomponent approaches to reduce risk factors of delirium as suggested by Inouye et al (33, 34) were included in routine care. For patients who had postoperative delirium develop, nonpharmacologic strategies were applied first (34) . Open-label haloperidol treatment was only reserved for those with severe agitation. An initial dose of 0.5 to 1 mg haloperidol was administered intravenously, repeated every 20 to 30 mins until agitation was effectively controlled (35) .
Outcome Assessments
The primary end point was the incidence of delirium during the first 7 days after surgery. Secondary end points included safety and tolerability of haloperidol administration, time to onset of delirium, daily prevalence of delirium, number of delirium-free days, and use of open-label haloperidol. Additional outcomes included time to extubation, length of stay in ICU, occurrence of other postoperative complications, length of stay in hospital after surgery, and all-cause 28-day mortality.
Outcome assessments were performed by research members who were not involved in clinical care of patients. Before the study, physicians performing assessment (H.L.L. and W.W.) were trained to follow standard procedures. They were also trained by a psychiatrist to use the confusion assessment method for the ICU (36, 37) . During the study phase, patients were assessed for delirium once daily (from 4:00 PM to 6:00 PM) in either the ICUs or the general wards (for those who had been discharged from ICU) until the seventh postoperative day.
Delirium assessment was performed in two steps. First, level of sedation (level of arousal) was assessed using the Richmond Agitation Sedation Scale. If the patient was deeply sedated or was unarousable (Ϫ4 or Ϫ5 on the Richmond Agitation Sedation Scale), then assessment was stopped and repeated later, and the patient was noted as comatose. If Richmond Agitation Sedation Scale was ϾϪ4 (Ϫ3 through ϩ 4), then assessment was continued to the next step. Second, delirium was diagnosed using the confusion assessment method for the ICU. It detects four features of delirium: acute onset of mental status changes or a fluctuating course; inattention; disorganized thinking; and altered level of consciousness. To have delirium diagnosed, a patient must display the first two aforementioned features, with either the third or fourth aforementioned feature.
Safety and tolerability were assessed by monitoring vital signs, electrocardiogram, and adverse events. Blood pressure and electrocardiogram were monitored continuously during ICU stay to check for episodes of hypotension and arrhythmia. Electrocardiogram was recorded in case of an adverse event and at the time of study drug discontinuation for evaluation of QTc interval. Significant QTc prolongation was defined as prolongation of QTc interval of Ͼ60 ms or QTc interval longer than 500 ms (38, 39) . Patients were clinically assessed hourly for signs of sedation and extrapyramidal symptoms. Adverse events were monitored until 24 hrs after surgery.
Patients were followed-up until 28 days after surgery. Postoperative complications were defined as medical events that required therapeutic intervention. All data were collected from the standardized patient records with a double-check manner.
Statistical Analysis
Sample Size Determination. The incidence of postoperative delirium in a comparable population of a previous study was 44.5% (8) . We assumed that the incidence of delirium would be 29.7% in the haloperidol group, i.e., a onethird reduction from the initial incidence. The calculated sample size that would provide 80% power to detect this difference based on a two-tailed significance level of 0.05 was 180 patients per group. The sample size calculation was performed on STATA 10.0 software (StataCorp, College Station, TX).
Efficacy and Safety Analysis. Intention-totreat analyses were performed. Continuous variables were analyzed with independent samples t test or Mann-Whitney U test. Categorical variables were analyzed with chisquare analysis or Fisher exact test. Times to onset of delirium, extubation, ICU discharge, and hospital discharge after surgery were calculated using Kaplan-Meier survival analyses, with differences between groups assessed by the log-rank test. Patients without onset of delirium were censored at the seventh postoperative day. Otherwise, they were censored at postoperative day 28.
A multivariate logistic regression model was used to determine whether the association between the intervention and the primary outcome was confounded by baseline differences. Baseline and perioperative variables that differed between the two groups (p Ͻ .10) were entered into the model.
Statistical analyses were performed on SPSS 14.0 software (SPSS, Chicago, IL). No interim analysis was planned or performed. Statistical tests were two-sided, and p Ͻ .05 were considered statistically significant. a Arrhythmia that required medical or interventional therapy; b serum creatinine Ͼ177 mol/L. c alanine transaminase and/or aspartate transaminase more than five-times the upper limit of normal; d smoking half a pack of cigarettes per day for at least 2 yrs; e two drinks or more daily, or weekly consumption of the equivalent of 150 mL of alcohol.
RESULTS
Patient Population
A total of 608 patients met the inclusion/exclusion criteria. Among them, 457 patients gave written informed consents and were randomized into the study. Study drug infusion was failed to initiate in four patients (three in the haloperidol group and one in the placebo group) because of heavy clinical workload. The results of these four patients were included in the final intention-to-treat analyses (Fig. 1) .
Baseline characteristics were similar between the two groups (Table 1) . Despite double-blind randomization, the durations of anesthesia and surgery were significantly longer, and the volume of total intraoperative infusion was significantly larger in the haloperidol group than in the placebo group. There were no significant differences with regard to other intraoperative and postoperative variables between the two groups ( Table 2) .
Efficacy Analyses
The incidence of postoperative delirium within the first 7 days after surgery was significantly lower in the haloperidol group than in the placebo group (15.3% [35/229] Figs. 2 and 3) .
Variables that differed between the two groups (p Ͻ .10) in Tables 1 and 2 were entered into a multivariate logistic regression analysis model, except for the duration of anesthesia, which was excluded because of collinearity with the duration of surgery (Pearson correlation coefficient ϭ 0.974; p Ͻ .001). The results showed that after adjustment for the duration of surgery, the estimated intraoperative bleeding, the total intraoperative infusion volume, and the type of surgery for malignant tumor, the odds ratio for the occurrence of postoperative delirium in the haloperidol group as compared with the placebo group was 0.574 (95% confidence interval 0.352-0.937; p ϭ .026).
Further analyses revealed that the time to onset of delirium and the number of delirium-free days during the first 7 postoperative days was significantly longer, whereas the length of ICU stay was significantly shorter in the haloperidol group than in the placebo group. However, the time to hospital discharge was similar between the two groups. There were no significant differences with regard to the incidences of nondelirium complications occurring within either 7 days or 28 days after surgery (Table 3 , Figs. 4 and 5A ).
Among patients who had postoperative delirium develop, the length of ICU stay was significantly shorter in the haloperidol group than in the placebo group. Furthermore, the incidence of nondelirium complications within 7 days after surgery was significantly less, and that within 28 days after surgery also tended to be less in the haloperidol group than in the placebo group (Table 4 , Fig. 5B ).
Treatment Safety
No ventricular arrhythmia or other significant adverse effects occurred during the period of study drug infusion. Therefore, no emergent unmasking of the treatment allocation was needed in all enrolled patients. The Richmond Agitation Sedation Scale results at the end of study drug infusion and the time to ex- e established with 250 mL of 0.12% ropivacaine plus 0.5 g/mL sufentanil, programmed to deliver a 2-mL bolus with a lockout interval of 20 mins and a background infusion of 4 mL/hr; f established with 100 mL of 0.5 mg/mL morphine, programmed to deliver a 2-mL bolus with a lockout interval of 6 -10 mins and a background infusion of 1 mL/hr; g calculated as total dose used during the first 7 postoperative days divided by body mass.
tubation were similar between the two groups ( Table 5 ).
The changes of QTc interval after study drug infusion were similar between the two groups. Significant QTc prolongation occurred in nine patients at the time of study drug discontinuation, among them four were in the haloperidol group and five were in the placebo group (p ϭ .995; Table 5 ). Detailed history reviews were conducted for these patients to find medications that might induce QT interval prolongation other than the study drug. Only one patient in the placebo group was found to be prescribed such medication (moxifloxacin) (40) . Allcause 28-day mortality was not significantly different between treatment groups and no death was considered related to study drug (Table 5) .
DISCUSSION
The present study demonstrated that in elderly patients admitted to ICU after noncardiac surgery, short-term prophylactic administration of low-dose intravenous haloperidol significantly decreased the incidence of delirium during the first 7 postoperative days. It also significantly prolonged the time to onset of delirium, increased the number of delirium-free days, and shortened the length of postoperative ICU stay. No drug-related side effects were documented.
The pathophysiology of delirium after anesthesia and surgery remains obscure and is thought to be multifactorial (34, 41) . Extensive evidence supported the role of cholinergic deficiency and/or dopaminergic excess (42, 43) . In fact, acetylcholine release is regulated by dopaminergic function, i.e., dopamine inhibits the release of acetylcholine by acting at dopamine D2 receptor, whereas blockade of D2 receptor is associated with enhanced release of acetylcholine (44, 45) . As a typical antipsychotic drug, haloperidol exerts its action by blocking dopamine D2 receptor (46) and continues to be the mainstay for the treatment of delirium in ICU patients (23) (24) (25) 47) . Therefore, it is reasonable to postulate that it might also be effective in the prevention of postoperative delirium.
A concern with the use of haloperidol prophylaxis is its potential side effects (hypotension, sedation, extrapyramidal symptoms, altered cardiac conduction, and others), which are usually dosedependent. Keeping the total daily dose Ͻ3 mg may reduce the risk of extrapyramidal side effects (48). Significant QTc prolongation had been reported in a patient with acute coronary syndrome after 2 mg of intravenous haloperidol (49) . For elderly patients, it has been suggested that haloperidol should be administered in the lowest possible doses for the shortest possible time (35) . In our study, haloperidol was administered intravenously by a bolus injection (0.5 mg), followed by a continuous infusion (at a rate of 0.1 mg/hr) for 12 hrs. The aim of bolus injection was to reach therapeutic blood level rapidly once the drug was started, and the bolus dose was chosen according to the suggested starting dose for treatment of delirium in elderly patients (35) . Haloperidol is commonly administered via intermittent intravenous injection in the critical care setting. However, a continuous intravenous infusion was used in our study to achieve a more consistent serum concentration (50, 51) . In contrast to other studies (15, 26) , we chose a much shorter prophylactic period. One reason was that we wanted to limit the CI, confidence interval. a Calculated using Kaplan-Meier survival analysis, with differences between groups assessed by the log-rank test;
b indicates the occurrence of brain dysfunction at any time during the first 7 days after surgery; c indicates that the patient was deeply sedated or unarousable (Ϫ4 or Ϫ5 on the Richmond Agitation Sedation Scale); d number of days alive without brain dysfunction during the first 7 days after surgery.
total dose of haloperidol on the first postoperative day (1.7 mg) to Ͻ2 mg to decrease the unwanted side effects. Another reason was that the incidence of delirium was highest on the first postoperative day and haloperidol has a relatively long halflife time (18 -54 hrs) (8, 30, 47) . Therefore, even after cessation of haloperidol infusion, its effects would continue and side effects might also occur. Because more than half of our patients stayed in the ICU for Ͻ24 hrs, we needed to observe the possible side effects for a time interval before they were moved to a general ward. Considering the low bioavailability after oral administration, the dosage of haloperidol used on the first postoperative day in our study was much higher than in the study of Kalisvaart et al (1.5 mg/day orally) (15) .
Apart from decreased incidence of postoperative delirium, it was found that the time to onset of delirium was significantly prolonged (mean, 0.5 day longer) and the number of delirium-free days was significantly increased (mean, 0.1 day more) by haloperidol prophylaxis. Because haloperidol can relieve certain symptoms of delirium (agitation or hyperactive symptoms), it is possible that patients receiving haloperidol might temporarily have their delirious symptoms masked during and immediately after the period of drug infusion, thus increasing the measure of delirium-free time. However, significantly shortened length of ICU stay (median, 1.7 hrs shorter in all patients and 21.8 hrs shorter in delirious patients) and lowered incidence of early postoperative complications (in delirious patients) implied that haloperidol might have changed the underlying course of delirium. Kalisvaart et al (15) also found that in patients who had delirium develop, haloperidol prophylaxis significantly decreased the severity and duration of delirium and shortened the length of hospital stay. In a retrospective cohort study, Milbrandt et al (52) reported that haloperidol use was associated with decreased mortality rate in mechanically ventilated patients. The clinical significances of a 0.1-day increase of deliriumfree time and a 1.7-hr decrease of ICU length of stay warrant further study.
It is worth noting that the incidence of postoperative delirium in the control group was lower than our previous result (23.3% vs. 44.5%) (8) . One possible reason is that the patient populations were not exactly the same. For example, although patients were older (74.2 Ϯ 6.5 yrs vs. 69.1 Ϯ 10.7 yrs), illness was less severe (Acute Physiology and Chronic Health Evaluation II score 8.6 Ϯ 2.9 vs. 9.8 Ϯ 4.6) in the present study. This probably resulted in a lower delirium incidence. Another possible reason is that the method of delirium assessment was different. In our previous study, delirium was assessed using the Nursing Delirium Screening Scale three times daily from the day of surgery, which might possibly detect more delirium cases (8, 53, 54) . The third possible reason is that routine patient care had been improved in the present study. Multicomponent preventive measures as suggested by Inouye et al (33, 34) were implemented after our previous study (55) and were included in the daily nursing care during the current study period.
The results of our study showed that no drug-related side effects were documented. No ventricular arrhythmia or episode of extrapyramidal symptoms occurred. No additive sedative effects were present. Furthermore, changes in QTc interval and occurrence of significant QTc prolongation after study drug infusion were similar between two groups. Therefore, the dose regimen of haloperidol used in our study was safe and effective, and it could be administered in critically ill elderly patients after noncardiac surgery.
The strengths of our study include randomization, inclusion of a placebo group, and blinding of research and healthcare personnel as well as patients to treatment allocation. However, there were several limitations of this study. First, we did not perform baseline psychiatric and cognitive screening tests. Preoperative mental disorders (such as depression, cognitive impairment, and dementia) may influence the occurrence of postoperative delirium (56, 57) . However, because this was a randomized controlled study, the confounding variables such as these should have been expected to present equally in the two groups. Second, intraoperative parameters were not similar. Although patients were randomly divided into two groups, the durations of anesthesia and surgery were significantly longer, and the volume of total intraoperative infusion was significantly larger in the haloperidol group than in the control group. However, according to literature, these differences indicated that patients in the haloperidol group were probably at higher risk for development of delirium (30, 58, 59) . After adjustment for these parameters, the odds ratio for the occurrence of postoperative delirium was still significantly lower in the haloperidol group than in the placebo group. Third, the incidence of postoperative delirium in the control group was lower than the anticipated results. The unexpected low incidence of delirium in the control group increased the risk of type 2 error. However, we did find differences between the two groups in the present study. All-cause 28-d mortality, number (%) 0 (0.0) 4 (7.5) .148
CI, confidence interval. a Calculated using Kaplan-Meier survival analysis, with differences between groups assessed by the log-rank test; b number of days alive without delirium during the first 7 days after surgery. Significant heart rate-corrected QT interval prolongation after study drug infusion b , n (%) indicate prolongation of heart rate-corrected QT interval of Ͼ60 ms or heart rate-corrected QT interval Ͼ500 ms; c these patients reported dry month during study drug infusion. However, these symptoms were judged to be possibly unrelated to the study drug; d calculated using Kaplan-Meier survival analysis, with differences between groups assessed by the log-rank test.
CONCLUSIONS
Our study demonstrated that for elderly patients admitted to ICU after noncardiac surgery, short-term prophylactic administration of low-dose intravenous haloperidol significantly decreased the incidence of delirium during the first 7 postoperative days. It also significantly delayed the onset of postoperative delirium. The clinical implications of a slight increase in delirium-free days and a slight decrease in ICU length of stay warrant further investigation.
